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Accepted 20 August 2012; Published online 16 March 2013AbstractObjective: To determine the comparability of subgroup-specific and interaction effects (differences between subgroups) between dif-
ferent study designs.
Study Design and Setting: We compared effects of interventions based on observational studies, randomized clinical trials (RCTs), and
individual patient data meta-analyses (IPDMAs) of RCTs (reference) on three clinical topics: (1) mammography screening and breast can-
cer mortality, (2) coronary artery bypass surgery (CABG) and all-cause mortality, and (3) statins and incidence of major coronary events.
Main, subgroup-specific, and interaction effects were compared.
Results: Main and subgroup-specific effects were comparable with respect to the direction of the effects. Differences in the magnitude
of subgroup-specific effects in observational studies yielded different interactions compared with those in IPDMA. In the mammography
example, the ratio of risk ratios (RRR) (i.e., interaction effect) among observational studies was 1.46 [95% confidence interval (CI): 1.09,
1.96] compared with an IPDMA effect of 1.10 (95% CI: 0.89, 1.37). For the CABG studies, the observational RRR was 1.03 (95% CI: 0.84,
1.26), whereas in the IPDMA, this was 1.40 (95% CI: 1.08, 1.1.81). Finally, in the statin example, the RRR was 1.35 (95% CI: 1.13, 1.61)
and 0.90 (95% CI: 0.84, 0.97) for observational studies and IPDMA, respectively.
Conclusion: Main and subgroup-specific effects based on observational data were similar to main and subgroup-specific effects in IPD-
MAs based on RCTs, yet interactions differed.  2013 Elsevier Inc. All rights reserved.
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Randomized clinical trials (RCTs) are the gold standard
to evaluate the effects of medical interventions. Typically,
randomized trials provide an estimate of the intervention
effect that applies to the average patient included in the
study. However, today’s clinical practice is shifting more
and more toward individually tailored care. Personalized
care requires knowledge on the effects of medical interven-
tions at an individual rather than at a patient population
level [1]. Compared with main effect estimates, subgroup
analyses move toward a more personalized estimate.
A distinction can be made between subgroup-specific ef-
fects (i.e., effects within subgroups of patients) and interac-
tion effects (i.e., difference between subgroup-specific
effects). When exploring subgroups, one may stratify the
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Key findings
 Main and subgroup-specific effects based on re-
ported observational data were similar in direction
compared with those from individual patient data
meta-analyses (IPDMAs). Differences in the mag-
nitude of observational subgroup-specific effects
caused observational interaction effects to differ.
What this adds to what was known?
 Prior research showed that main effects based on
observational data can be similar to those based
on RCT data. In our three examples, subgroup-
specific effect estimates were also similar across
randomized and nonrandomized designs. However,
despite this similarity, interaction effects differed.
What is the implication and what should change
now?
 Before conducting an RCT or IPDMA and after
critical evaluation of the observational data, evi-
dence based on observational studies should receive
more attention. However, researchers should be
aware that similarity of main or subgroup-specific
effects does not imply similarity of interaction ef-
fects across different designs.
study population, which decreases the sample size. Hence,
differences in effects between subgroups are more likely to
occur simply because of chance, and therefore, it is recom-
mended to perform a formal test of interaction [2,3]. Fur-
thermore, if one is interested to test whether effects of
medical interventions differ between subgroups (i.e., inter-
action effects), exploring subgroup-specific effects is inap-
propriate [2,4].
An individual RCT is often underpowered to detect inter-
action effects because of sample size constraints [4]. Alterna-
tively, data from multiple RCTs can be pooled in an
individual patient data meta-analysis (IPDMA) [5,6], in
which interaction effects can be evaluated. Nevertheless, con-
ducting an IPDMA, based on RCTs, is not always feasible.
Alternatively, observational (i.e., nonrandomized) studies,
which typically comprise larger sample sizes, can be used
to explore subgroup effects. Observational data, however,
have limitations [7], such as the potential for confounding.
Although numerous techniques and designs have been
proposed to control for confounding [8], few can account
for unobserved (i.e., unmeasured) confounding. In particu-
lar, observational studies of intended effects of interven-
tions are at risk for confounding bias [9e12]. Moreover,
observational studies are also hampered by other problems
such as the potential for selection and information bias. Arelated issue is that RCTs tend to include healthier subjects
compared with the general patient population [13]. On the
other hand, several authors showed that high-quality obser-
vational studies of intended effects often display main ef-
fects that are comparable with those obtained from RCTs
[14e16].
Whether observational-based (i.e., based on nonrandom-
ized data), subgroup-specific, and interaction effect esti-
mates can also approximate results of RCTs or IPDMA
of RCTs remains unknown. We therefore conducted a re-
view of three clinical examples to evaluate the comparabil-
ity of effect estimates obtained from different study designs
(e.g., observational, RCT, and IPDMA).2. Methods
2.1. Search strategy
IPDMAs were identified using the ‘‘IPD Cochrane
Methods Group’’ Web site [17] and MEDLINE database.
IPDMAs were deemed suitable if they (1) explored sub-
groups based on patient characteristics at baseline, (2) al-
lowed for direct comparison of subgroup-specific effects,
(3) reported sufficient data to calculate point estimates of
the treatment effects with confidence intervals (CIs), (4)
were based on RCTs, and (5) were written in English.
Subsequently, we searched for (additional) RCTs and
observational articles. First, we searched MEDLINE and
the CENTRAL databases with an adapted search strategy,
used by the original IPDMAs to also include observational
studies (Appendix A at www.jclinepi.com). This search
was supplemented with a Scopus [18] cross-reference
search. We performed this strategy on five preselected do-
mains: mammography screening in breast cancer mortality,
antibiotics in rhinosinusitis, antibiotics in acute otitis me-
dia, phenytoin in epileptics, and carboplatin in ovarium
cancer survival [19e23]. This strategy only yielded enough
observational studies for the mammography [23] example
to facilitate a meaningful comparison.
Additionally, we searched MEDLINE for IPDMAs and
systematic reviews that included RCTs and/or observa-
tional studies. The reference lists of these reviews were
searched for relevant publications, which we subsequently
retrieved and screened for inclusion. We used Scopus to
search for additional references. This search resulted in
two additional post hoc examples: coronary artery bypass
surgery (CABG) vs. percutaneous coronary intervention
(PCI) on all-cause mortality and statin therapy in the pre-
vention of cardiovascular events [24,25].
RCTs and observational studies were included when
they (1) investigated similar patients, interventions, and
outcomes as the IPDMA; (2) investigated similar
subgroup-specifics that allowed for direct comparison of
treatment effects; (3) allowed calculation of point estimates
and CI of the treatments effects; (4) used an RCT, cohort
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glish. We deemed an example viable if we found two or
more observational studies that were comparable with the
IPDMA. Because a meta-analysis based on individual pa-
tient data from RCTs allows the researcher to uniformly
apply subgroup-specific cut-off points, choose similar end-
points and adjustment for confounding when necessary, we
considered IPDMAs as the reference standard [6]. To check
whether pooled estimates of reported studies could approx-
imate IPDMA results, we explored reported RCT estimates,
including the IPDMA RCTs [26,27].
2.2. Statistical analysis
Extracted data were analyzed using R, version 2.10 for
windows [28]. When available, we used effect measures
that were adjusted for possible differences in baseline cova-
riates between comparison groups.
We used reported effect measure and if necessary calcu-
lated subgroup-specific effects based on reported data. Ef-
fects were reported in risk ratios or rate ratios (RR),
hazard ratios (HRs) [29e32], or odds ratios (ORs; for casee
control studies) with 95% CI. In all cases in which ORs or
HRs were used, the incidence was 10% for both main and
subgroup-specific outcomes, fulfilling the rare disease as-
sumption [33]. Prespecified subgroups included age groups
(in the examples on mammography screening and statin
therapy) and diabetes presence or absence (CABGFig. 1. Effects of mammography screening on breast cancer mortality, strati
RR, risk ratio or rate ratio; CI, confidence interval; RCT, randomized clinica
resent pooled summary measures.example). For the observational and RCT effects, measures
of heterogeneity (Q-statistic (Q), I-squared (I2), and tau-
squared (t2) [34]) were calculated, and pooled effects were
estimated using fixed- and random-effects models. In all the
three design types, an interaction test was performed. This
was done by taking the ratio of the stratum-specific effects
[2]. This resulted in a ratio of risk ratios (RRR). When
RRR 5 1, there is no interaction effect (i.e., no differences
of treatment effect between subgroup); RRR ! 1 indicates
a smaller effect of treatment in one subgroup compared
with that in the reference group; RRRO 1 indicates a larger
effect of treatment in one subgroup compared with that in
the reference group. To obtain a standard error (SE) for
the 95% CI, we squared stratum-specific SE of which we
took the square root of the sum. For the observational and
RCT data, the RRR was based on the ratio of subgroup-spe-
cific random effects results. For the IPDMA, the RRR was
based on the reported subgroup-specific estimates. In the
Results section, we state which reference groups were used.3. Results
3.1. Effect of mammography screening by age
The IPDMA of Nystrom et al. [23] determined the ef-
fects of mass mammography screening vs. no screening
on breast cancer mortality. To study the effectiveness offied by study design. RR! 1 indicates protective effect of screening.
l trials; IPDMA, individual patient data meta-analyses. Diamonds rep-
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stratified the results by age,!50 and 50 years, which re-
sulted in a nonsignificant interaction test. The data of the
IPDMA could be compared with six trials (of which four
were included in the IPDMA) [35e40] and six observa-
tional studies (one cohort study [41] and five caseecontrol
studies [42e46]). The IPDMA included 247,010 women, of
whom 1,642 died of breast cancer, whereas in the RCTs,
392,483 women participated, of whom 1,645 died of breast
cancer. The observational studies included 233,791 women,
of whom 4,498 died of breast cancer. Overall, the included
studies were similar regarding the intervention, control
group, and outcome parameter (see Appendix B at www.
jclinepi.com).
The pooled main effect of mammography screening on
breast cancer mortality (Fig. 1) in RCTs, IPDMA, and ob-
servational data were RR, 0.77 (95% CI: 0.69, 0.84); RR,
0.85 (95% CI: 0.77, 0.93); and RR, 0.65 (95% CI: 0.54,
0.78), respectively.
When data were stratified by age (women younger than
50 years and 50 years or older), a similar pattern was ob-
served (Fig. 2). In younger women, the effects of mammog-
raphy screening were similar, irrespective of type of study
design. In older women, however, the effect in the individ-
ual observational studies was larger than that observed in
the IPDMA, but the direction of effect was in agreement.
In the IPDMA, RCTs, and observational data, the interac-
tion effects (RRR) in young women compared with thoseFig. 2. Effects of mammography screening on breast cancer mortality in stra
screening. Extreme values were truncated. Interaction effects are the ratio o
subjects. RR, risk ratio or rate ratio; CI, confidence interval; RCT, randomiz
ratio of risk ratio. Diamonds represent pooled summary measures.in older women were 1.10 (95% CI: 0.89, 1.37), 1.17
(95% CI: 0.94, 1.47), and 1.46 (95% CI: 1.09, 1.96),
respectively.3.2. Effect of CABG (vs. PCI) by diabetes status
Hlatky et al. [25] studied the effect CABG vs. PCI on all-
cause mortality using an IPDMA (including 10 trials).
Hlatky stratified the main effects for numerous baseline
characteristics including the presence of diabetes, which
produced a significant interaction (P 5 0.014). The data of
the IPDMA could be compared with five trials [47e51]
(which were all included in the IPDMA), and three observa-
tional cohort studies [31,32,52]. The IPDMA included 7,812
subjects who underwent a CABG or PCI procedure, of
whom 1,203 died. The total sample size of the RCTs was
6,087 subjects, of whom 807 died. The cohort studies in-
cluded 23,629 subjects, of whom 866 died. The number of
diabetes patients varied according to the study design type:
6,561 (27.76%) in the IPDMA; 5,197 (21.99%) in the RCTs;
and 11,720 (49.60%) in the cohort studies.
The pooled main effects were comparable for the differ-
ent designs: RR 5 0.86, 95% CI: 0.79, 0.94 (observational
studies); RR 5 0.86, 95% CI: 0.72, 1.00 (RCTs); and
RR 5 0.92, 95% CI: 0.83, 1.02 (IPDMA). See also Fig. 3.
The effect estimates of CABG (vs. PCI) in the group of
nondiabetic patients were similar in the cohort studies,
RCTs, and IPDMA, showing no effect (Fig. 4). However,ta of younger and older subjects. RR! 1 indicates protective effect of
f effect in younger (!50 years) divided by effect in older (50 years)
ed clinical trials; IPDMA, individual patient data meta-analyses; RRR,
Fig. 3. Effects of CABG vs. PCI on all-cause mortality, stratified by
study design. RR! 1 indicates protective effect of CABG. CABG, cor-
onary artery bypass surgery; PCI, percutaneous coronary intervention;
RR, risk ratio or rate ratio; CI, confidence interval; RCT, randomized
clinical trials; IPDMA, individual patient data meta-analyses. Dia-
monds represent pooled summary measures.
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tive effect, whereas the observational studies showed no ef-
fects. This remained after pooling the subgroup-specific
effects. The ratio of the effects in nondiabetics compared
with diabetics (Fig. 4) showed that performing CABG (vs.
PCI) was more effective in preventing all-cause mortality
in diabetics compared with nondiabetics: RRR 5 1.40,
95% CI: 1.08, 1.81 (in IPDMA). The interaction effect basedFig. 4. Effects of CABG vs. PCI on all-cause mortality in strata of nondiabetic
values were truncated. Interaction effects are ratio of the effect in nondiabe
percutaneous coronary intervention; RR, risk ratio or rate ratio; CI, confiden
data meta-analyses; RRR, ratio of risk ratio. Diamonds represent pooled suon RCTs (RRR5 1.34, 95% CI: 0.83, 2.17) was comparable
with the IPDMA effect, albeit nonsignificant, whereas the
interaction effect based on observational studies
(RRR 5 1.03, 95% CI: 0.84, 1.26) was smaller.
3.3. Effect of statin therapy by age
The Cholesterol Treatment Trialists’ Collaborators [24]
IPDMA studied the effect of statin therapy vs. placebo or
an active comparison group on a composite of cardiovascular
endpoints (n 5 14 trials). The IPDMA explored numerous
subgroups including a significant (P 5 0.01) interaction by
age (65/O65) on major coronary events. Because the
screened RCTs and observational studies mostly reported
subgroup-specific effects by age, here, we focus on this sub-
group. The data of the IPDMA could be compared with six
RCTs [30,53e57] (of which five were included in the IPD-
MA), and four observational studies (three cohort studies
[29,58,59] and one caseecontrol study [60]). The IPDMA
consisted of 90,056 subjects, of whom 7,757 developed the
outcome of interest. In the RCTs, 70,877 subjects were in-
cluded, of whom 8,192 developed a major coronary event.
The observational studies comprised 50,553 subjects, of
whom 22,219 participated in cohort studies and 28,334 in
the caseecontrol study; 2,485 cases were included by these
studies. The cohort study described by Poluzzi et al. did not
report the number of cases for the primary prevention group
in which they stratified for age. Heterogeneity in interven-
tions, comparisons, and outcomes was large in the IPDMA,
RCTs, and observational studies. For example, interventions
differed in type and dosage of statins, age dichotomizations and diabetics. RR! 1 indicates protective effect of CABG. Extreme
tics by effect in diabetics. CABG, coronary artery bypass surgery; PCI,
ce interval; RCT, randomized clinical trials; IPDMA, individual patient
mmary measures.
Fig. 5. Effects of statin therapy on cardiovascular endpoints, stratified
by study design. RR ! 1 indicates protective effect of statins. RR,
risk ratio or rate ratio; CI, confidence interval; RCT, randomized clin-
ical trials; IPDMA, individual patient data meta-analyses. Diamonds
represent pooled summary measures.
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placebo controlled to active comparison in RCTs, and from
active comparison to adherence to therapy in the observa-
tional studies (see Appendix B at www.jclinepi.com).
The main effects (RRs) observed in the IPDMA, RCTs,
and observational studies were 0.75 (95% CI: 0.72, 0.79),
0.79 (95% CI: 0.71, 0.89), and 0.65 (95% CI: 0.53, 0.78),
respectively (Fig. 5).
When stratifying the results by age groups and pooling
the individual studies, the estimates of the RCTs and obser-
vational studies were in concordance with the IPDMA
(Fig. 6). The exception to this was the older subgroup in
the observational study, in which the effect was smaller
(but in the same direction) than the effect found in the IPD-
MA. The interaction effects (RRR) in young vs. older sub-
jects were 0.90 (95% CI: 0.84, 0.97), 0.97(95% CI: 0.84,
1.12), and 1.35 (95% CI: 1.13, 1.61) in IPDMA, RCTs,
and observational studies, respectively.
4. Discussion
In the three clinical examples that we presented, main
and subgroup-specific effects for observational studies were
in agreement with those found in RCTs and IPDMA. This
was not the case for interaction effects. In the mammogra-
phy example, observational studies showed a significant
interaction, whereas RCTs and the IPDMA did not. How-
ever, the interaction effect was in the same direction. In
the other two examples, observational-based interaction
effects showed either no effect or an effect in the opposite
direction compared with RCTs and IPDMAs.
These results are in agreement with earlier studies
which also found comparable main effect estimatesbetween RCTs and observational studies [14e16]. The
novelty of our study is that we compared subgroup-
specific and interaction effects in IPDMAs, RCTs, and
observational studies. We urge readers to be aware that
similarity of effects between observational and RCT stud-
ies is topic specific and depends on the likelihood of mea-
suring all important confounders. Because RCTs are not
hampered by the potential of unmeasured confounding,
they are typically preferred over observational studies to
assess the effects of medical interventions. This research
showed that, despite the potential of confounding by indi-
cation and inclusion of potentially different patient popula-
tions, main and subgroup-specific effects derived from
observational data can, at least in our three examples, re-
semble IPDMA-based estimates.
Our study has several limitations that need to be ad-
dressed. An important limitation of our study is that we in-
cluded only three clinical examples. Furthermore, although
we tried to search systematically in the literature, we may
have missed studies. Additionally, we concede that requir-
ing our examples to comprise at least two observational
studies and two RCT studies is arbitrarily chosen and in-
creasing, this threshold would obviously decrease the num-
ber of example presented here. It seems highly unlikely,
however, that these issues would lead to a bias that favors
comparability of reported results.
Second, differences in confounding adjustment and
other analytical discrepancies might have influenced our re-
sults. For example, all RCTs conducted an intention-to-
treat (ITT) analysis, whereas most observational studies
did not but conducted an as-treated analysis instead. In
the mammography example, this may have led to a dilution
of effects in RCTs compared with the observational studies
[61,62]. The TEDBC [41] observational study analyzed
their data based on screening vs. nonscreening center (an
analysis more similar to ITT) and found no interaction ef-
fect, which is in line with IPDMA. Furthermore, for other
examples, we were unable to extract adjusted subgroupe
specific effects (either they were not presented adequately
or not performed). For example, only the CABG study by
Malenka et al. [32] reported adjusted subgroupespecific ef-
fects. However, they only adjusted for ‘‘number of diseased
coronary arteries.’’ This may have resulted in a somewhat
biased subgroup-specific estimate, in which it seemed that
diabetics, with a higher mortality risk (e.g., morbidity bur-
den diabetics), were more likely to receive CABG interven-
tion. Similarly, in the statin example, only the cohort study
by Poluzzi et al. [59] adjusted for confounding in sub-
groups, for instance by using a categorized age variable
(!50, 50e65, 65e80, andO80 years). However, this does
not sufficiently exclude residual confounding. In this case,
lack of adjustment revealed a healthy user bias, in which
healthy older subjects received, or complied the most with,
the strictest drug therapy.
Third, apart from differences in analyses, factors such as
duration of follow-up, comparison group treatment, and
Fig. 6. Effects of statin therapy on cardiovascular endpoints in strata of younger and older subjects. RR! 1 indicates protective effect of statins.
Extreme values were truncated. Interaction effects are the ratio of the effect in younger subjects (!60e70 years) divided by effect in older subjects
(O60e70 years). RR, risk ratio or rate ratio; CI, confidence interval; RCT, randomized clinical trials; IPDMA, individual patient data meta-analyses;
RRR, ratio of risk ratio. Diamonds represent pooled summary measures.
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between studies. Our examples were also harmed by this;
follow-up duration ranges were 8.8e18 years in the mam-
mography example, 5.6e10.4 years in the CABG example,
and 0.5e8 years in the statin example. Furthermore, al-
though treatment and outcomes were very similar in the
mammography and CABG examples (Appendix B at
www.jclinepi.com), in the statin example, RCTs used pla-
cebo or active comparison groups, whereas observational
studies used no or diminished treatment adherence as
a comparator group.
Fourth, we concede that using IPDMA based on RCTs
as a gold standard is not unattested. For example, RCTs
are known to include relatively healthier patients and in-
crease compliance toward unrealistic levels, which might
be unattainably in clinical practice. Hence, estimates of
treatment effects based on RCTs could overestimate the
treatment effects observed in daily practice which conse-
quently also results in differences in effect estimates.
Finally, a different issue is that exploring multiple
subgroup-specific and interaction effects increases the
type-1 error rate. This results in confidence intervals that
are smaller than 95% and therefore increase the likelihood
of finding a false-positive result. The impact of multiple
testing, however, is unlikely to differ between observational,
RCT, and IPDMAs. Despite above described shortcomings
we still found agreement for main and subgroup-specific
effect across differently designed studies. However, it is
possible that using more appropriate observational (IPD)data, some of these issues could be solved which in turn
might increase the similarity between interaction effects
based on observational and RCTs studies.
In conclusion, main and subgroup-specific effects based
on reported observational data were similar in direction to
those from IPDMAs. Interaction effects found in RCTs and
IPDMAs were also similar. In two examples, observational-
based interaction effects showed different direction of effects
compared with RCTs and the IPDMA estimates. Similarity of
main and subgroup-specific effects across designs therefore
does not imply similarity of interaction effects.Acknowledgments
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